Shilpa Medicare gets final approval for OERIS in India
Shilpa Medicare received final approval from India’s Subject Expert Committee under CDSCO to market OERIS, its extended-release ondansetron injection.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.